---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274543"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:26:04.242764+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ResMed appoints new CPO, CMO, CRO; COO Douglas to retire Jan 1, 2024

## Summary
- Rob Douglas, President & COO, retires Jan 1, 2024; transitions to special advisor to CEO immediately.
- Justin Leong named Chief Product Officer, Katrin Pucknat as CMO, Mike Fliss as CRO, effective immediately.
- Lucile Blaise moves from president sleep & respiratory care to SVP strategy & business development.
- New operating model sets product-led, customer-centric, brand-enhanced focus to accelerate profitable growth.
- Former CTO Urvashi Tyagi becomes special advisor to CPO through Jan 1, 2024; consulting through Dec 31, 2024.

## SEC filing metadata
- accession: 0001193125-23-274543
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312523274543/0001193125-23-274543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312523274543/d287548d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274543
- JSON: https://secwatch.observer/filing/0001193125-23-274543.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274543.txt

## Key facts
- Executive change
  Robert Douglas retired as special advisor to the CEO at RESMED INC.
  - Action: retired
  - Role: special advisor to the CEO
  source text: On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/943819/000119312523274543/0001193125-23-274543-index.htm
- Executive change
  Robert Douglas changed role as special advisor to the CEO at RESMED INC.
  - Action: transitioned
  - Role: special advisor to the CEO
  source text: On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/943819/000119312523274543/0001193125-23-274543-index.htm
- Executive change
  Lucile Blaise changed role as senior vice president, strategy & business development at RESMED INC.
  - Action: transitioned
  - Role: senior vice president, strategy & business development
  source text: Lucile Blaise, our former president, sleep & respiratory care, will transition to a role as senior vice president, strategy & business development, reporting to our Chief Strategy Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/943819/000119312523274543/0001193125-23-274543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.